Posts Tagged ‘Invokana’

Glucuretics: Great Diabetic Control, Piss-Poor Urinary Control

July 31, 2021

Andrew Siegel MD    7/31/2021 My father’s 90th birthday! Happy birthday dad!

Pardon the vulgarity, but the slang term “piss-poor” is to the point–both literally and figuratively–of this entry.

Thumbs up diabetic control; thumbs down urinary control

Image by Tumisu from Pixabay 

Fact: Type 2 diabetes is epidemic.

Fact: A commonly used, highly effective medication class to help regulate blood sugar is the glucuretic class, which lowers blood sugar by eliminating it in urine, hence the name “gluc” meaning sugar and “uretic” meaning occurring in the urine.

Fact: The collateral adverse effects of spilling sugar in the urine can be significant, often driving patients to seek urological consultation.

Diabetes impairs the regulation and utilization of glucose, resulting in elevated blood sugar and potential problems with the vascular (circulatory) and nervous systems that may compromise virtually every organ in the body. Either the pancreas produces insufficient amounts of insulin and/or the body’s cells have a poor response to the insulin that is produced (insulin resistance), resulting in elevated levels of glucose in the blood and a host of symptoms that often include thirst, urinary frequency, blurry vision, fatigue, hunger, weight loss, poor wound healing and infections.

First line management of Type 2 diabetes is lifestyle modification (weight loss, healthy eating habits, exercise, etc.) that can sometimes obviate the need for medications. However, medications are often required to optimize glucose control. The short-term aim of diabetic control and lowering blood glucose is to provide relief from the presenting symptoms–thirst, urinary frequency, blurry vision, etc.–and the long-term goal is to prevent the microvascular (diseased small blood vessels) consequences of retinopathy (visual disease), nephropathy (kidney disease) and neuropathy (nerve disease).

Optimization of diabetic control often requires several different medications.  Fortunately, there are many families of effective medications available with different mechanisms of action. One family decreases glucose production by the liver; another helps the body produce more insulin; another increases sensitivity to insulin; another helps lower blood glucose; yet another family—the SGLT2 inhibitors—decrease levels of glucose by excretion through the kidneys.

The SGLT2 inhibitors include Invokana (canagliflozin), Farxiga (dapagliflozin), Jardiance (empagliflozin) and Steglatro (ertugliflozin). SGLT is an acronym for sodium-glucose-co-transporter 2, a protein that is responsible for the kidneys reabsorbing glucose back into the body. These medications work by blocking the action of SGLT in the kidney, increasing glucose levels in the urine and decreasing glucose levels in the blood. Invokana was the first medication of this class, approved by the FDA in 2013.

SGLT2 Inhibitors Glucuretics

–Invokana

–Farxiga

–Jardiance

–Stelatro

The long and short of it is that the SGLT2 inhibitors work effectively by eliminating excess glucose via the urine.  But at what cost? 

URINARY ISSUES RESULTING FROM GLUCOSE IN THE URINE

Diabetics are prone to urinary issues and the presence of glucose in the urine can “add kerosene to the fire.” For a general discussion of diabetes and urological health, please see: Diabetes and Urological Health.

Irritative lower urinary tract symptoms: When glucose is present in the urine it acts as an osmotic diuretic (glucose carries water with it causing large volumes of urine to be made by the kidneys). Recall that many diabetics before they were formally diagnosed with diabetes initially present with urinary frequency as a result of the osmotic diuretic effect of glucose in the urine. This increases the rate of urine production and thus the bladder fills that much faster with urine.  This can cause urinary urgency, the need to hustle to the bathroom in a hurry, urinary frequency and sleep interruption, and even urgency incontinence.  If a patient has pre-existing overactive bladder, they will likely have an exacerbation of their symptoms on an SGLT2 inhibitor.

Genital yeast infections: Another common consequence of glucose in the urine is genital yeast infections, both yeast vaginitis in females and yeast balano-posthitis (infection of head of penis and foreskin) in males. After urination, some urine inevitably will be retained within the vagina and foreskin, and the presence of the dark, moist, warm environment with added glucose are ideal circumstances for yeast overgrowth.

Urinary tract infections: Another consequence of glucose in the urine is the promotion of urinary infections.  Diabetics are already at higher risk for urinary tract infections and add a little glucose to the urine and you have a recipe for a “bacterial bacchanal”!  This might end up being bacterial cystitis in a female or bacterial prostatitis in a male, but on occasion it can be an extremely serious and life-threatening infection of the soft tissues of the genitals and perineum, known as a necrotizing fasciitis of the perineum, a.k.a. Fournier’s gangrene. 

Bottom Line: The SGLT2 inhibitors are an effective class of drugs for managing Type 2 diabetes, but caveat emptor regarding the consequences of having glucose in the urine. As a urologist, I see many patients in the office with urinary side effects of glucuretic medications, and many were never forewarned about these.  The SGLT2 inhibitors are particularly detrimental in patients with recurrent urinary tract infections, recurrent yeast infections, and overactive bladder.  Patients are often requested to go back to their diabetic specialists to seek an alternative class of diabetic medications that does not adversely affect the urinary system.

Wishing you the best of health,

This image has an empty alt attribute; its file name is signature.jpg
This image has an empty alt attribute; its file name is always-bring-homework.jpeg

A new blog is posted weekly. To receive a free subscription with delivery to your email inbox visit the following link and click on “email subscription”:  www.HealthDoc13.WordPress.com

Dr. Andrew Siegel is a physician and urological surgeon who is board-certified in urology as well as in female pelvic medicine and reconstructive surgery.  He is an Assistant Clinical Professor of Surgery at the Rutgers-New Jersey Medical School and is a Castle Connolly Top Doctor New York Metro Area, Inside Jersey Top Doctor and Inside Jersey Top Doctor for Women’s Health. His mission is to “bridge the gap” between the public and the medical community. He is a urologist at New Jersey Urology, the largest urology practice in the United States.  He is the co-founder of PelvicRx and Private Gym.  His latest book is Prostate Cancer 20/20: A Practical Guide to Understanding Management Options for Patients and Their Families. 

This image has an empty alt attribute; its file name is pc2020-cover.png

Video trailer for Prostate Cancer 20/20

Preview of Prostate Cancer 20/20

Andrew Siegel MD Amazon author page

PROSTATE CANCER 20/20 is now available at Audible, iTunes and Amazon as an audiobook read by the author (just over 6 hours). 

Dr. Siegel’s other books:

FINDING YOUR OWN FOUNTAIN OF YOUTH: The Essential Guide to Maximizing Health, Wellness, Fitness and Longevity

PROMISCUOUS EATING— Understanding and Ending Our Self-Destructive Relationship with Food

MALE PELVIC FITNESS: Optimizing Sexual and Urinary Health

THE KEGEL FIX: Recharging Female Pelvic, Sexual, and Urinary Health

Video on THE KEGEL FIX